Drug Use among Nursing Home Residents in Denmark for Drugs Having Pharmacogenomics Based (PGx) Dosing Guidelines: Potential for Preemptive PGx Testing

Drug Use among Nursing Home Residents in Denmark for Drugs Having Pharmacogenomics Based (PGx) Dosing Guidelines: Potential for Preemptive PGx Testing

Background: Polypharmacy is most prevalent among the elderly population and in particular among nursing home residents. The frequency of the use of drugs with pharmacogenomics (PGx)-based dosing guidelines for CYP2D6, CYP2C9, CYP2C19 and SLCO1B1 were measured among nursing home residents in the Capi...

Full description

Bibliographic Details
Main Authors:	Charlotte Vermehren, Regitze Søgaard Nielsen, Steffen Jørgensen, Anne Mette Drastrup, Niels Westergaard
Format:	Article
Language:	English
Published:	MDPI AG 2020-07-01
Series:	Journal of Personalized Medicine
Subjects:	nursing homes polypharmacy medicine review pharmacogenomics cytochrome P450 SLCO1B1
Online Access:	https://www.mdpi.com/2075-4426/10/3/78

Similar Items

Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients
by: Niels Westergaard, et al.
Published: (2020-01-01)

Comparison of Multidrug Use in the General Population and among Persons with Diabetes in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines
by: Niels Westergaard, et al.
Published: (2021-09-01)

Pharmacogenomic (PGx) Counseling: Exploring Participant Questions about PGx Test Results
by: Tara Schmidlen, et al.
Published: (2020-04-01)

Population Pharmacogenomics in Croatia: Evaluating the PGx Allele Frequency and the Impact of Treatment Efficiency
by: Vid Matišić, et al.
Published: (2023-08-01)

Editorial: Population Pharmacogenomics (PGx): From Variant Identification to Clinical Implementation
by: Masahiro Hiratsuka, et al.
Published: (2021-08-01)

Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
by: Theodore J. Wigle, et al.
Published: (2017-12-01)

Pharmacogenomics (PGx) Patient with Mixed Levels of Actionable Variant Evidence
by: Michael J. Schuh, et al.
Published: (2020-05-01)

Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy
by: Niels Westergaard, et al.
Published: (2021-02-01)

Cardiovascular precision medicine – A pharmacogenomic perspective
by: Sandosh Padmanabhan, et al.
Published: (2023-01-01)

The pharmacogenomics of pain management: prospects for personalized medicine
by: Ting S, et al.
Published: (2016-02-01)

Identification of Drugs Acting as Perpetrators in Common Drug Interactions in a Cohort of Geriatric Patients from Southern Italy and Analysis of the Gene Polymorphisms That Affect Their Interacting Potential
by: Mauro Cataldi, et al.
Published: (2023-08-01)

Genetic variations in the drug metabolizing enzyme, CYP2E1, among various ethnic populations of Pakistan
by: Sagheer Ahmed, et al.
Published: (2020-08-01)

Pharmacogenomics polygenic risk score for drug response prediction using PRS-PGx methods
by: Song Zhai, et al.
Published: (2022-09-01)

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
by: Ann K. Daly, et al.
Published: (2017-12-01)

Pathway-targeted pharmacogenomics of CYP1A2 in human liver
by: Kathrin eKlein, et al.
Published: (2010-11-01)

Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer Patients
by: Heather Randles, et al.
Published: (2019-12-01)

Cross-comparison of exome analysis, next-generation sequencing of amplicons, and the iPLEX® ADME PGx Panel for pharmacogenomic profiling
by: Eng Wee eChua, et al.
Published: (2016-01-01)

Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study
by: Margarita-Ioanna Koufaki, et al.
Published: (2023-06-01)

ADME Gene-Related Pharmacogenomic Labeling of FDA-Approved Drugs: Comparison with Clinical Pharmacogenetics Implementation Consortium (CPIC) Evidence Levels
by: Subrata Deb, et al.
Published: (2024-02-01)

Pharmacogenomics: introduction and use in clinical practice
by: Saunders Hollie, et al.
Published: (2020-06-01)

Editorial: Pharmacogenomics: From Bench to Bedside and Back Again
by: Jeffrey A. Shaman, et al.
Published: (2022-03-01)

A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study
by: Teuntje A. D. Pelgrim, et al.
Published: (2024-01-01)

Drug-drug interactions between Highly Active Antiretroviral Therapy and Antiblastic chemotherapy in cancer patients with HIV infection
by: Massimiliano eBerretta, et al.
Published: (2016-03-01)

Conversion Disorder in a Pharmacogenomics, Polypharmacy Patient: Case Report
by: Michael J. Schuh, et al.
Published: (2021-11-01)

Pharmacogenomics in drug discovery and development /
by: Yan, Qing, 1971-
Published: (2008)

Pharmacogenomics Testing Confirmation of Carbamazepine Induced DRESS Reaction of an HLA-A*31:01 Positive, Polypharmacy Patient
by: Leigh Speicher, et al.
Published: (2021-12-01)

Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial
by: Céline K. Stäuble, et al.
Published: (2021-12-01)

Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450
by: Viktor Hlaváč, et al.
Published: (2020-08-01)

Additional Utility of Pharmacogenomics (PGx) Panel Testing in a CYP2D6 Normal Metabolizer with a History of Breast Cancer
by: Michael Schuh
Published: (2019-07-01)

Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children
by: Ida Aka, et al.
Published: (2017-11-01)

Pharmacogenomics of cytochrome P450 3A4 (CYP3A4): recent progress towards the missing heritability problem
by: Kathrin eKlein, et al.
Published: (2013-02-01)

Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study
by: Vasileios Fragoulakis, et al.
Published: (2023-11-01)

Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing
by: William J. Canestaro, et al.
Published: (2012-10-01)

Improving the Care of Older Patients by Decreasing Potentially Inappropriate Medications, Potential Medication Omissions, and Serious Drug Events Using Pharmacogenomic Data about Variability in Metabolizing Many Medications by Seniors
by: Roger E. Thomas
Published: (2020-09-01)

Increased risk of aspirin-induced gastric mucosal erosion in elderly Chinese men harboring SLCO1B1*1b/*1b while using aspirin and an ACEI or ARB concomitantly
by: Lei Duan, et al.
Published: (2019-11-01)

Are we PREPAREd? Concerning the “PREemptive Pharmacogenomics Testing for Preventing Adverse Drug Reactions (PREPARE) Study”
by: Ana de Carmo Campos, et al.
Published: (2023-10-01)

PHARMACOGENOMICS OF HUMAN P450 OXIDOREDUCTASE
by: Amit V Pandey, et al.
Published: (2014-05-01)

Pharmacogenetics of schizophrenia in real clinical practice: a clinical case
by: R. F. Nasyrova, et al.
Published: (2018-12-01)

SLCO1B1 and ABCG2 Gene Polymorphisms in a Thai Population
by: Rattanacheeworn P, et al.
Published: (2020-10-01)

Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial
by: Nicholas L. Syn, et al.
Published: (2018-07-01)